The medical device market in China is showing phenomenal growth, which is expected to continue over the coming years. Valued at $14.8 billion in 2010, the Chinese medical device market is forecast to grow to a value of $30.6 billion by 2017 at a compound annual growth rate (CAGR) of 10.9% (see Figure 1).
According to 'China Medical Devices Industry - A Market Snapshot and Key Company Profiles', a report from market analysis company GlobalData, the Chinese medical device industry grew at a CAGR of 8.9% over the past seven years, which is higher than the growth rate of the medical devices markets in many developed economies. As a result, it is currently ranked second in the Asia-Pacific region and fourth globally in terms of revenue.
China's medical device industry consists both of domestic and foreign multinational players. Domestic manufacturers vastly outnumber the foreign multinationals, but in terms of market share the foreign firms rule, accounting for 70% of the market's total value. Foreign multinationals dominate the capital and technology-intensive markets such as cardiovascular devices and imaging technology.
On the other hand, local manufacturers enjoy a strong presence in markets such as wound-care management, surgical equipment and in vitro diagnostic reagents, specifically in the less technology-intensive areas such as the manufacturing of disposables, bandages and surgical instruments. A healthy reversal of this trend is gradually being seen, with the growing presence of Chinese companies - such as Mindray Medical International, Shandong JW Medical Products Co, Shandong Weigao Group Medical Polymer Company and Neusoft Medical Systems - in highly technological intensive segments like cardiovascular equipment, diagnostic imaging devices and healthcare IT.
Healthcare reforms drive growth
In November 2008, the Chinese Government announced an overall fiscal stimulus package of approximately 6 trillion yuan, out of which around 850 billion yuan was earmarked for healthcare stimulus. In 2009, it announced a five-point reform programme covering: the establishment of a medical security system; reforming pharmaceutical distribution and pricing mechanisms; the penetration of healthcare at a grass-roots level; restructuring public healthcare institutions; and encouraging private partnerships in public healthcare institutions.
The Chinese Government will invest nearly $120 billion over the next three years to implement the reforms at various levels. These changes, which mainly focus on improving the healthcare infrastructure, are expected to increase the size of the Chinese healthcare market by 12-15% annually in the coming years.
Cost benefits in manufacturing
China has a population base of 1.3 billion and offers a labour force in excess of 800 million, more than five times the labour force of the US in 2009 (150 million). Of the 800 million, about 60% are employed in sectors that are technology intensive, providing a huge pool of skilled workers at comparatively cheap cost. The remaining 40% of the workforce is employed in agriculture or related activities where the application of technology is relatively low. These workers contribute to a pool of seasonal migratory workers with a relatively lower set of skills.
Potential flaws in reform
Critics of the healthcare reforms have pointed to some potential flaws that may hamper the full positive impact of the policies. A few of these are:
- Although the government announced a subsidy of 120 yuan per capita, this is much less than the per capita total healthcare expenditure of 1,400 yuan in 2010. Therefore, despite the reforms, the general public has to bear the majority share when it comes to payment of medical bills. As a result, the healthcare reforms may not significantly change the healthcare spending trend of the Chinese population.
- The reforms require the patient to pay for their medical bills and doctors visits upfront, which get reimbursed later. This is a problem for the poor and middle-class segments of the population, who can find it difficult to pay huge medical bills all at once, discouraging them from visiting healthcare institutions.
- China's significant migrant rural population does not qualify for state welfare programmes and healthcare services. Bringing them under the umbrella of these healthcare reforms is a major challenge for the government.
A highly fragmented market
According to a report by the Canadian Foreign Affairs and International Trade Center, there are more than 13,000 Chinese medical device manufacturers. In addition to this, there are significant numbers of foreign manufacturers dominating the high-technology medical devices market. As a result of such intense competition, it is very difficult for any manufacturer to gain a significant market share in any segment.
Since the organic growth in such an intensely competitive market is very slow, many companies are taking the route of inorganic growth through mergers, acquisitions and joint ventures.
This article was first published in our sister publication Medical Device Developments.